Anti-BRCC36 antibody (ab62075)
Key features and details
- Rabbit polyclonal to BRCC36
- Suitable for: WB, ICC/IF, IHC-P
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-BRCC36 antibody
See all BRCC36 primary antibodies -
Description
Rabbit polyclonal to BRCC36 -
Host species
Rabbit -
Tested applications
Suitable for: WB, ICC/IF, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Raised against an 18 amino acid peptide from near the amino terminus of human BRCC36.
-
Positive control
- MCF7 nuclear lysate
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab62075 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 0.5 - 1 µg/ml. Detects a band of approximately 36 kDa.
|
|
ICC/IF |
Use a concentration of 20 µg/ml.
|
|
IHC-P |
Use a concentration of 2.5 µg/ml.
|
Notes |
---|
WB
Use a concentration of 0.5 - 1 µg/ml. Detects a band of approximately 36 kDa. |
ICC/IF
Use a concentration of 20 µg/ml. |
IHC-P
Use a concentration of 2.5 µg/ml. |
Target
-
Function
Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). -
Tissue specificity
Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors. -
Involvement in disease
A chromosomal aberration involving BRCC3 is a cause of pro-lymphocytic T-cell leukemia (T-PLL). Translocation t(X;14)(q28;q11) with TCRA. -
Sequence similarities
Belongs to the peptidase M67A family. BRCC36 subfamily.
Contains 1 MPN (JAB/Mov34) domain. -
Cellular localization
Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with FAM175B/ABRO1 retains BRCC3 in the cytoplasm (PubMed:20656690). - Information by UniProt
-
Database links
- Entrez Gene: 79184 Human
- Omim: 300617 Human
- SwissProt: P46736 Human
- Unigene: 558537 Human
-
Alternative names
- BRCA1-A complex subunit BRCC36 antibody
- BRCA1/BRCA2 containing complex subunit 3 antibody
- BRCA1/BRCA2 containing complex subunit 36 antibody
see all
Images
-
Lane 1 : Anti-BRCC36 antibody (ab62075) at 0.5 µg/ml
Lane 2 : Anti-BRCC36 antibody (ab62075) at 1 µg/ml
Lane 3 : Anti-BRCC36 antibody (ab62075) at 2 µg/ml
All lanes : MCF7 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : anti-rabbit IgG
Observed band size: 36 kDa why is the actual band size different from the predicted? -
ab62075 at 2.5 µg/ml staining BRCC36 in human brain tissue section by Immunohistochemistry (Formalin/ PFA fixed paraffin-embedded sections).
-
Immunofluorescence of BRCC36 in Human Brain cells using ab62075 at 20 ug/ml.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab62075 has been referenced in 3 publications.
- Wang CY et al. BRCA1/BRCA2-containing complex subunit 3 controls oligodendrocyte differentiation by dynamically regulating lysine 63-linked ubiquitination. Glia 67:1775-1792 (2019). PubMed: 31184779
- Biswas K et al. BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage. Nat Commun 9:537 (2018). PubMed: 29416040
- Zhang F & Zhou Q Knockdown of BRCC3 exerts an anti-tumor effect on cervical cancer in vitro. Mol Med Rep 18:4886-4894 (2018). PubMed: 30272359